Study Title
P-105-202: Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of ALVR105 (Viralym-M) Compared to Placebo for the Prevention of AdV, BKV, CMV, EBV, HHV-6, and JCV Infection and/or Disease, in High-Risk Patients After Allogeneic Hematopoietic Cell Transplant.
Protocol ID
P-105-202
Disease (Sub Disease)
Adenovirus Infection
BK Virus Infection
Cytomegalovirus Infections
Epstein-Barr Virus Infections
Human Herpes Virus-6 Infection
JC Virus Infection
BK Virus Infection
Cytomegalovirus Infections
Epstein-Barr Virus Infections
Human Herpes Virus-6 Infection
JC Virus Infection
Sponsor
AlloVir
Links
Trial Status
Temporarily Closed
Study Type
Observational
Phase
Phase 3
Age Eligibility
Child, Adult, Older Adult
International registry ID's
NCT05305040
| Study Title | P-105-202: Phase 2/3 Multicenter Randomized Double-Blind Placebo-Controlled Study to Assess the Safety and Efficacy of ALVR105 (Viralym-M) Compared to Placebo for the Prevention of AdV BKV CMV EBV HHV-6 and JCV Infection and/or Disease in High-Risk Patients After Allogeneic Hematopoietic Cell Transplant. |
|---|---|
| Protocol ID | P-105-202 |
| Disease (Sub Disease) | Adenovirus Infection BK Virus Infection Cytomegalovirus Infections Epstein-Barr Virus Infections Human Herpes Virus-6 Infection JC Virus Infection |
| Sponsor | AlloVir |
| Links | https://clinicaltrials.gov/ct2/show/NCT05305040 |
| Trial Status | Temporarily Closed |
| Trial Open Date | 31/03/2023 |
| Study Type | Observational |
| Phase | Phase 3 |
| Age Eligibility | Child, Adult, Older Adult |
| International registry ID's | NCT05305040 |